Search | Clinical Trials Finder

Conditions: Healthy Volunteers
Interventions: LY2484595 Reference Formulation (RF), LY2484595 spray-dried solid dispersion-propyl gallate (SDSD-PG); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Glendale, California

Conditions: Dermatitis Atopic
Interventions: Amlitelimab, Placebo, Topical corticosteroids, Topical calcineurin inhibitors; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 40
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Encino, California + 32 more

Conditions: Hepatitis C, HIV Infections
Interventions: Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 2
States / cities: Cincinnati, Ohio • Richmond, Virginia

Conditions: Actinic Keratosis
Interventions: Imiquimod, Zyclara®, Vehicle Cream; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 467 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 27
States / cities: Birmingham, Alabama • Fremont, California • Los Angeles, California + 23 more

Conditions: Stress
Interventions: Theanine for stress relief formulation, Placebo; Dietary Supplement
Lead sponsor: Supplement Formulators, Inc.; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Healthy Volunteers
Interventions: RO7017773 Phase I Capsule, RO7017773 Phase II Tablet Unflavored, RO7017773 Phase II Tablet Sweetened/Flavored; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Pterygium
Interventions: CBT-001, Vehicle; Drug
Lead sponsor: Cloudbreak Therapeutics, LLC; Industry
Eligibility: 12 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 20
States / cities: Dothan, Alabama • Sun City, Arizona • Bakersfield, California + 16 more

Conditions: Pediculus Humanus Capitis, Head Lice
Interventions: Placebo, BGC20-0582; Drug
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 2 Years to 70 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Florida City, Florida

Conditions: Childhood Absence Epilepsy, Petit Mal Epilepsy, Epilepsy, Seizures
Interventions: Ethosuximide, Lamotrigine, Valproic acid; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 30 Months to 13 Years
Enrollment: 453 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2016
U.S. locations: 31
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 28 more

Conditions: Chemotherapy-induced Peripheral Neuropathy
Interventions: ATX01 10%, ATX01 15%, Placebo; Drug
Lead sponsor: AlgoTherapeutix; Industry
Eligibility: 18 Years and older
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 8
States / cities: Clermont, Florida • Miami, Florida • Port Charlotte, Florida + 5 more

Conditions: Osteoarthritis of the Knee
Interventions: TLC599, DSP; Drug
Lead sponsor: Taiwan Liposome Company; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 7
States / cities: Phoenix, Arizona • Miami, Florida • Charleston, South Carolina + 2 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Treatment A (BGF MDI HFO with oral activated charcoal), Treatment B (BGF MDI HFA with oral activated charcoal); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Healthy Participants
Interventions: Rozanolixizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: San Antonio, Texas • Salt Lake City, Utah

Conditions: Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
Interventions: Biospecimen Collection, Computed Tomography, Fluorouracil, Gemcitabine, Irinotecan, Irinotecan Sucrosofate, Leucovorin, Nab-paclitaxel, Panitumumab, Questionnaire Administration; Procedure · Drug · Biological + 1 more
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 274
States / cities: Anchorage, Alaska • Phoenix, Arizona • Fayetteville, Arkansas + 207 more

Conditions: Chronic Weight Management
Interventions: ASC35 Injection B, for subcutaneous use, ASC35 Placebo Injection B, for subcutaneous use, Tirzepatide; Drug
Lead sponsor: Ascletis Pharma (China) Co., Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: Pregabalin controlled release, 330 mg, 400 to 500 calorie, Pregabalin controlled release, 330 mg, 600- 750 calorie, Pregabalin controlled release, 330 mg, bedtime, Pregabalin immediate release, 300 mg; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Acute Kidney Injury (Nontraumatic)
Interventions: CXA-10 emulsion, Placebo; Drug
Lead sponsor: Complexa, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Sunscreening Agents
Interventions: BAY987517, Untreated skin; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Piscataway, New Jersey

Conditions: Antibiotic Resistant Strain
Interventions: Autologous fecal microbiota transplant (Auto-FMP Enema), Placebo Enema Preparation; Biological · Other
Lead sponsor: Microbiome Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Insomnia
Interventions: E2006; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy
Interventions: Amlodipine Besylate, Norvasc; Drug
Lead sponsor: Torrent Pharmaceuticals Limited; Industry
Eligibility: 18 Years to 45 Years
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSV (GSK3389245A) low dose formulation vaccine, RSV (GSK3389245A) middle dose formulation vaccine, RSV (GSK3389245A) high dose formulation vaccine, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 23 Months
Enrollment: 107 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 6
States / cities: Anaheim, California • Aurora, Colorado • Topeka, Kansas + 3 more

Conditions: Bipolar Disorder, Depression, Bipolar
Interventions: Ziprasidone, Placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 60
States / cities: Chandler, Arizona • Litchfield Park, Arizona • Little Rock, Arkansas + 50 more

Conditions: Sunscreening Agent
Interventions: Coppertone (BAY 987517); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Union, New Jersey

Search by objective public record fields.

A Study of LY2484595 in Healthy Subjects

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids

Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIV

A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participants With Actinic Keratoses

Effects of a Theanine for Stress Relief Formulation in Individuals Who Report Occasional Moderate High Levels of Stress.

A 2 Part Study to Assess the Relative Bioavailability of Tablet Formulation Compared to Capsule Formulation and the Effect of Food and Taste Assessment on the Tablet Formulation in Healthy Participants

A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium

A Study Evaluating the Safety and Efficacy of BGC20-0582 Lice Treatment Gel for Head Lice Infestation

Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study

Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy)

A Phase 2, Open Label, Pharmacokinetic (PK) Study of TLC599 in Subjects With Osteoarthritis of the Knee

Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant

A Study to Assess the Concentration of Rozanolixizumab in the Breast Milk of Healthy Lactating Women

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or Overweight

Investigation Of Absorption And Pharmacokinetics Of A Single Dose Of Controlled Release Pregabalin Tablet Administered Fasted At Bedtime Or Immediately Following A 400-500 or 600-750 Calorie Evening Meal As Compared To Single Dose Of Immediate Release Pregabalin Capsule In Healthy Volunteers

Study of CXA-10 in Healthy Volunteers

Human Photoallergy Test (824/2016)

Autologous Fecal Microbiota Transplantation to Prevent Antibiotic Resistant Bacteria Colonization

Open-Label Study of Bioavailability of E2006 Tablet Versus Capsule Formulations

Study to Evaluate the Bioavailability of the Test Formulation of Amlodipine 10 mg Tablets (Torrent Pharmaceuticals Limited) Compared to a 10 mg Dose of Norvasc® (Pfizer) in 18 Fed, Healthy Adult Subjects

A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants

Adjunctive Ziprasidone in the Treatment of Bipolar I Depression

Sun Protection Factor Assay (SPF Assay 18677)